Clinical Trial Update: 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating resminostat (4SC-201) in combination with sorafenib for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Resminostat (resminostat)

Snippet

Sponsor: 4SC AG | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED